International Stem Cell Corp (ISCO)

Name: International Stem Cell Corp (ISCO) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name International Stem Cell CORP · CIK 0001355790 · OTC · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, International Stem Cell Corp reported revenue of $9.10M. Revenue grew 0.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $9.51M.

Key ratios (year ended 2025-12-31)

55.7%

Gross margin (computed)

-2.9%

Operating margin

-4.6%

Net margin

0.2%

Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-17

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$9.51M	$9.10M	$9.09M	$7.79M	$8.18M	$7.18M	$7.13M	$9.47M	$11.09M	$7.46M	$7.17M
Cost of Revenue	$4.29M	$4.03M	$3.76M	$3.18M	$3.27M	$2.94M	$2.78M	$3.93M	$4.07M	$2.12M	$1.94M
Gross Profit (computed)	$5.23M	$5.07M	$5.32M	$4.61M	$4.91M	$4.24M	$4.35M	$5.54M	$7.02M	$5.33M	$5.22M
R&D Expense	$646.0K	$684.0K	$657.0K	$511.0K	$492.0K	$695.0K	$988.0K	$1.39M	$2.40M	$2.66M	$2.86M
Operating Income	-$444.0K	-$267.0K	-$68.0K	-$663.0K	-$183.0K	-$1.92M	-$2.82M	-$5.73M	-$3.47M	-$4.94M	-$4.85M
Depreciation & Amortization	$171.0K	$219.0K	$206.0K	$194.0K	$218.0K	$262.0K	$253.0K	$285.0K	$308.0K	$326.0K	$331.0K
EBITDA	-$273.0K	-$48.0K	$138.0K	-$469.0K	$35.0K	-$1.66M	-$2.56M	-$5.44M	-$3.17M	-$4.62M	-$4.52M
Net Income	-$582.0K	-$418.0K	-$209.0K	-$131.0K	-$331.0K	-$899.0K	-$2.72M	-$4.26M	-$2.13M	-$6.07M	-$1.08M
EPS (Diluted)	n/a	-$0.05	-$0.03	-$0.02	-$0.04	-$0.11	n/a	n/a	-$0.33	-$1.46	-$0.34
Total Assets	$5.06M	$4.82M	$5.17M	$5.39M	$5.13M	$4.95M	$5.29M	$6.62M	$7.80M	$6.86M	$7.04M
Total Liabilities	$4.98M	$4.58M	$4.80M	$5.28M	$5.36M	$5.23M	$5.32M	$5.21M	$5.26M	$4.80M	n/a
Shareholders' Equity	-$4.23M	-$4.06M	-$3.93M	-$4.19M	-$4.52M	-$4.59M	-$4.33M	-$2.89M	$2.54M	$2.06M	$3.44M
Cash & Equivalents	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	$304.0K	$110.0K
Operating Cash Flow	$369.0K	$8.0K	$13.0K	$929.0K	$332.0K	-$1.30M	-$341.0K	-$1.40M	-$1.08M	-$2.14M	-$4.20M
Capital Expenditures	$36.0K	$43.0K	$166.0K	$80.0K	$1.0K	$23.0K	$28.0K	$164.0K	$185.0K	$112.0K	$231.0K
Free Cash Flow	$333.0K	-$35.0K	-$153.0K	$849.0K	$331.0K	-$1.32M	-$369.0K	-$1.56M	-$1.27M	-$2.25M	-$4.43M
Shares Outstanding	8.00M	8.00M	8.00M	8.00M	8.00M	8.00M	7.54M	7.54M	6.93M	6.06M	3.95M
Weighted Average Diluted Shares	n/a	8.00M	8.00M	8.00M	8.00M	7.83M	n/a	n/a	6.39M	4.16M	3.19M
EPS (Basic)	n/a	-$0.05	-$0.03	-$0.02	-$0.04	-$0.11	n/a	n/a	-$0.33	-$1.46	-$0.34